Mission Statement, Vision, & Core Values (2026) of Bonesupport Holding AB (publ).

Step into the world of BONESUPPORT Holding AB, a Scandinavian innovator reshaping orthobiologics with its injectable bio-ceramic CERAMENT® that remodels into a patient's own bone within six to twelve months, a company whose global footprint spans over 30 countries and direct sales in Europe and the United States, and whose 2024 performance - SEK 898.7 million in net sales, a striking 52% year‑over‑year increase - underscores the market momentum behind minimally invasive solutions for trauma, chronic osteomyelitis and foot & ankle surgery; guided by a mission to restore structural integrity and quality of life for patients with bone voids, a vision to lead in first‑in‑class bone remodeling and drug‑eluting composites, and core values of innovation, quality, integrity, collaboration and accountability that have driven sustained R&D investment (including a reported SEK 66 million allocation in 2018) and clinical adoption worldwide.

Bonesupport Holding AB (0RQO.L) - Intro

• Flagship product: CERAMENT® - injectable bio-ceramic that remodels to native bone within 6-12 months.
• Global footprint: commercial presence in over 30 countries; direct sales in Europe and the U.S.
• Clinical focus: trauma, chronic osteomyelitis, foot & ankle procedures.

• Advance bone health by delivering clinically proven, easy-to-use regenerative solutions that improve patient outcomes and reduce complications.

• To be the global leader in minimally invasive orthobiologics, transforming the standard of care for bone repair through science-driven innovation and scalable commercial execution.

• Patient-centricity - prioritize safety, efficacy and predictable healing timelines.
• Innovation - continuous R&D investment to improve materials, formulations and clinical indications.
• Clinical evidence - commitment to rigorous clinical studies and real-world data to support adoption.
• Global collaboration - build strong local partnerships and direct commercial capabilities to ensure access.
• Integrity & compliance - adhere to regulatory standards and ethical commercialization practices.

• Scale high-growth markets - ramp direct U.S. and European sales to capitalize on rising adoption reflected in 52% revenue growth in 2024.
• Invest in R&D and evidence generation - sustained research spend to expand indications and support long-term remodeling claims (historical R&D: SEK 66 million in 2018).
• Optimize product portfolio - broaden CERAMENT® applications and delivery formats for surgical and minimally invasive procedures.
• Strengthen reimbursement and hospital adoption pathways - align clinical data with payer requirements to accelerate uptake.

Bonesupport Holding AB (0RQO.L) - Overview

• Core therapeutic focus: bone void management and bone regeneration.
• Primary commercial products: bone graft substitutes and resorbable carriers for local antibiotic delivery (e.g., CERAMENT family).
• Strategic objectives: expand global adoption, strengthen clinical evidence, and broaden product pipeline.

• Vision: become a global leader in orthobiologics for bone void repair and infection management.
• Clinical evidence: continued investment in randomized studies, registries, and real-world outcome tracking to demonstrate improved healing rates and reduced complications.
• Commercial roll-out: targeted expansion in key markets (EU, UK, US) through distributor partnerships and direct sales in higher-potential territories.

• Patient-centricity: outcomes and quality of life improvements as primary KPIs.
• Innovation: iterative product development and evidence generation in orthobiologics.
• Integrity & compliance: adherence to regulatory standards across jurisdictions.
• Collaboration: partnerships with clinicians, hospitals, and payors to enable access.

• Number of surgical procedures using CERAMENT products: cumulative hundreds of thousands globally (adoption growing across orthopedics and trauma).
• Evidence base: multiple peer-reviewed studies and ongoing randomized trials measuring bone healing rates, infection control, and functional outcomes.
• Patient outcomes targeted: reduced non-union rates, lower infection recurrence, faster functional recovery, and improved quality-adjusted life years (QALYs).

• Expand US commercial footprint and reimbursement access to increase US share from ~20% toward parity with Europe.
• Progress ongoing clinical trials and publish outcomes to drive guideline inclusion and hospital adoption.
• Optimize manufacturing and supply chain to support scale and margin improvement.
• Monitor and manage cash runway while balancing growth investments and pathway to profitability.

Bonesupport Holding AB (0RQO.L) - Mission Statement

• Deliver first-in-class injectable bio-ceramic products with bone remodeling and drug-eluting capabilities (e.g., Cerament series).
• Reduce surgical morbidity via minimally invasive, injectable solutions for bone void management.
• Integrate anti-infective drug-elution to lower post-operative infection rates and improve healing timelines.
• Drive evidence generation-clinical, imaging and health-economic-to support adoption and reimbursement.
• Scale global access through regulatory approvals, strategic partnerships and direct sales expansion.

• Clinical impact targets: reduce infection-related re-operation rates by meaningful percentages versus historical controls (published studies report lowered local infection recurrence in select cohorts).
• Health-economics focus: shorten hospitalization and downstream resource utilization via faster graft incorporation and infection control, supporting payer discussions.
• Commercial KPIs: expand surgeon adoption, increase case volumes per market, and grow recurring revenue from single-use injectable devices.

Bonesupport Holding AB (0RQO.L) Vision Statement

• Bring best-in-class local antibiotic and bone-regenerative solutions to orthopaedic surgeons globally
• Scale adoption in major markets (US, EU, APAC) while expanding evidence through real-world data and randomized clinical trials
• Drive sustained commercial growth while investing in R&D to broaden indications and improve patient outcomes

• Innovation - Continuous product development (new formulations, delivery formats), supported by clinical programs to improve outcomes for osteomyelitis, fracture care and bone void management.
• Quality - Stringent quality systems, regulatory compliance across CE, FDA pathways and other jurisdictions; quality controls embedded from manufacturing to clinical follow-up.
• Integrity - Transparent reporting, ethical patient and physician engagement, and adherence to regulatory and governance standards.
• Collaboration - Partnerships with hospitals, KOLs, distributors and payors to accelerate adoption and generate robust clinical evidence.
• Accountability - Clear ownership of targets across functions (commercial, clinical, regulatory, manufacturing), with metrics and reviews to ensure delivery.

• Innovation: Allocate R&D resources to expand indications and improve handling/antibiotic delivery; pursue regulatory clearances supported by clinical endpoints (infection eradication, radiographic bone healing).
• Quality: Maintain ISO/CE compliance and meet FDA requirements where applicable; implement post-market surveillance and complaint handling metrics.
• Integrity: Public financial reporting and governance aligned with Stockholm listing requirements; transparent clinical communications and disclosure practices.
• Collaboration: Structured KOL programs, hospital partnerships, and distributor agreements to drive adoption and collect outcomes data.
• Accountability: KPI-driven commercial targets, clinical trial milestones, and manufacturing quality metrics with clear ownership across teams.